Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 8/20 | 0.62 |
| ▸ | CA2 | P00918 | 8/20 | 0.62 |
| ▸ | CA9 | Q16790 | 8/20 | 0.62 |
| ▸ | CA14 | Q9ULX7 | 8/20 | 0.62 |
| ▸ | ESR1 | P03372 | 10/20 | 0.59 |
| ▸ | ESR2 | Q92731 | 9/20 | 0.59 |
| ▸ | DRD1 | P21728 | 1/20 | 0.54 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.48 |
| ▸ | CA7 | P43166 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6713488 | 0.93 | ESR1 (0.61) | CA1CA2CA9CA14ESR1 | |
| SCHEMBL6715323 | 0.92 | ESR1 (0.66) | CA1CA2CA9CA14ESR1 | |
| SCHEMBL6715430 | 0.88 | ESR1 (0.56) | CA1CA2CA9CA14ESR1 | |
| SCHEMBL19439363 | 0.88 | CA1 (0.62) | CA1CA2CA9CA14ESR1 | |
| SCHEMBL5512737 | 0.88 | CA1 (0.63) | CA1CA2CA9CA14ESR1 | |
| SCHEMBL6713170 | 0.87 | ESR1 (0.57) | CA1CA2CA9CA14ESR1 | |
| SCHEMBL6716747 | 0.86 | DRD1 (0.54) | CA1CA2CA9CA14ESR1 | |
| SCHEMBL6723053 | 0.83 | ESR1 (0.85) | ESR1ESR2 | |
| SCHEMBL6716260 | 0.83 | DRD1 (0.56) | CA1CA2CA9CA14ESR1 | |
| SCHEMBL28742357 | 0.82 | CA1 (0.69) | CA1CA2CA9CA14DRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040192685-A1 | Tetrahydroisoquinoline compounds as estrogen agonists/antagonists | CAMERON KIMBERLY O (US) | 2004-09-30 | — | — | US | disclosed |
| US-20030220494-A1 | Tetrahydroisoquinoline compounds as estrogen agonists/antagonists | CAMERON KIMBERLY O (US) | 2003-11-27 | — | — | US | disclosed |
| US-6608203-B2 | Devoid of unwanted side effects | PFIZER INC. | 2003-08-19 | — | — | US | disclosed |
| US-20010039285-A1 | Tetrahydroisoquinoline compounds as estrogen agonists/antagonists | CAMERON KIMBERLY O (US) | 2001-11-08 | — | — | US | disclosed |
| EP-1113007-A1 | Tetrahydroisoquinoline compounds as estrogen agonists/antagonists | PFIZER INC. (US) | 2001-07-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010039285-A1 | Tetrahydroisoquinoline compounds as estrogen agonists/antagonists | GPER1, ESR1, ESR2 | CA1 4479/4885CA2 4638/4885CA9 4369/4885 |
| US-20030220494-A1 | Tetrahydroisoquinoline compounds as estrogen agonists/antagonists | GPER1, ESR1, ESR2 | CA1 4479/4885CA2 4638/4885CA9 4369/4885 |
| US-20040192685-A1 | Tetrahydroisoquinoline compounds as estrogen agonists/antagonists | GPER1, ESR1, ESR2 | CA1 4479/4885CA2 4638/4885CA9 4369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.